Author: News Room

© Reuters FOSTER CITY, Calif. – Gilead Sciences, Inc. (NASDAQ: NASDAQ:) has reached a definitive agreement to acquire CymaBay Therapeutics, Inc. (NASDAQ: NASDAQ:) for $32.50 per share in cash, amounting…